Saol Therapeutics Receives FDA Complete Response Letter for SL1009 (DCA) for Pyruvate Dehydrogenase Complex Deficiency

Saol Therapeutics announced that the FDA issued a Complete Response Letter (CRL) for their New Drug Application (NDA) of SL1009 (Sodium Dichloroacetat...